For the study, researchers tracked 1,070 kids aged 12 to 18 who were overweight or obese and also had a diagnosis of asthma.

Marketed as Exdensur, the ultra-long-acting biologic is the first of its kind, requiring only two injections per year to ...

An asthma treatment that only requires patients to have two jabs a year to prevent life-threatening attacks will be available ...

Two replicate phase 3 trials of GB-0895, an anti-thymic stromal lymphopoietin antibody, are enrolling adults and adolescents ...

Diagnosing precisely what type of asthma a child has and fine-tuning the treatment for it involves an invasive procedure under general anesthesia. For children with mild asthma, it's just not worth ...

The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype, GSK announced.

What can you do to help your eosinophilic asthma treatments work their best? There are simple steps you can take each day to improve symptoms, quality of life, and overall health. Eosinophilic asthma ...

Asthma is a very common condition and, while it’s treatable, there’s always a need for new options. Researchers at Trinity College Dublin have now found that an inflammatory “off switch” molecule ...

Coughing and wheezing can leave anyone wondering whether it is asthma or bronchitis at play. Both of these respiratory issues ...

As the prevalence of asthma continues to increase, the financial impact on the healthcare costs of the United States does as well. Managed care pharmacists are ideally situated to unite the shared ...

Asthma is common. Around 10 percent of Americans have the condition, with hundreds of millions more asthmatics worldwide. Though the ubiquity of asthma may be concerning in and of itself, it's a ...

This year’s top asthma and respiratory disorder story focused on the pushback from multiple advocacy groups following ...